MD-ESAB-CORPORATION
18.11.2022 21:36:36 CET | Business Wire | Press release
Today ESAB, part of ESAB Corporation (NYSE: ESAB), and a world leader in welding and cutting equipment and consumables, unveiled the industry-changing Renegade VOLT™ ES 200i Stick/TIG battery-powered welding system as it closed out SparkWeek, the brand’s week-long, virtual launch event highlighting new welding and fabrication products, automation and robotics solutions, and industry-shaping PPE.
Developed in conjunction with Stanley Black & Decker and powered by four DEWALT® FLEXVOLT® 12 Ah (amp-hour) batteries, the Renegade VOLT marks a crossroads for the welding industry, as ESAB establishes a new product category. For the first-time welders have a battery-powered welding machine which operates on interchangeable, rechargeable power tool batteries. The VOLT is a highly portable option for off-the-grid welding across key industries like maintenance and repair, construction, shipyard, rail, power generation, offshore and farm/agriculture. The product will be available for purchase in Q1 2023.
"ESAB has continuously brought new ideas to the market since the invention of the first coated welding electrode more than a century ago. With the Renegade VOLT, we have taken the idea of portability and supercharged it,” said Olivier Biebuyck, President, EMEA and Global Products, ESAB Corporation. “Up until now, welding jobs have only gone as far as the equipment could reach. Welders were stuck lugging around heavy leads, tripping over cables, and wondering what kind of power would be at the job site. Sometimes welders even spent more time on job set up and breakdown than welding. Today, ESAB eliminated those constraints and ushered in a new age. This is the age of true welding freedom. No cords and heavy leads, no time-consuming setup, no engines, or fuel."
The VOLT launch capped off a string of new and re-imagined solutions from ESAB which were unveiled during SparkWeek. The company made more than 15 announcements between Monday, November 14 and Friday, November 18 via dynamic, live video premieres at ESAB.com/SparkWeek. The event page now features information about these new products and partnerships, including key specifications and availability information:
- Ruffian 150, ESAB’s all-new engine-driven welder
- Rogue EM and Rogue EMP, MIG and multi-process machines
- Rustler, a completely new ESAB line of compact MIG machines
- Renegade 1 Ph DC, powerful-yet-lightweight machine now in single-phase power
- Warrior EDGE CX System with RobustFeed Edge CX and Exeor torch, a next-generation pulse-MIG power source, feeder, and torch product family
- Sentinel A60, the next iteration of ESAB’s industry-leading automatic welding helmet
- Swarm A10, A20, and A30, affordable, performance driven welding helmet portfolio
- Vision T6, easy-to-use CNC cutting machine controller
- Marathon Pac Ultra, a new 1,100-lb. bulk welding wire drum package
- Cutmaster 30+, next-generation manual plasma cutter focused on power and portability
- Thermal Dynamics Automation UC Series, a high precision mechanized plasma system
- Victor Edge 2.0 Phase IV and HRF2400, gas regulator and a regulator/flowmeter combination
- Versotrac Cadet, a compact, efficient, and easy to use submerged arc welding (SAW) tractor
- InduSuite, advanced software that connects welding and cutting data, machinery, and processes across one platform
- PURUS, new and improved premium wire specially formulated to reduce post-weld cleaning
ESAB products are available globally for purchase through select distributors and retail locations. Visit ESAB.com to find a local distributor and learn more about the product portfolio.
About ESAB
ESAB is a world leader in fabrication technology. For more than 100 years ESAB has transformed industries built by fabricators, providing complete workflow solutions through our diverse portfolio of products from more than 40 of the most trusted brands in welding and cutting in the world. From industrial demands to repair and maintenance, innovators that shape the world, rely on ESAB’s portfolio. To learn more, visit ESAB.com.
About ESAB Corporation
ESAB Corporation (NYSE: ESAB) is a world leader in fabrication and gas control technology, providing our partners with advanced equipment, consumables, gas control equipment, robotics, and digital solutions which enable the everyday and extraordinary work that shapes our world. To learn more, visit ESABcorporation.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20221118005574/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
KATE Launches "KABUKE: Break Convention" Kabuki-Inspired International Campaign17.7.2026 09:00:00 CEST | Press release
Where “NO MORE RULES.” intersects with the Kabuku spirit. Inspired by Japanese aesthetics, KATE shares the value of shadow enhancing makeup and self‑expression with the world. Global cosmetics brand KATE launched “KABUKE: Break Convention,” a new international campaign drawing on elements of Kabuki, the traditional Japanese performing art. The campaign debuted on Wednesday, July 8, 2026. In this campaign, KATE’s shadow enhancing makeup—rooted in Japanese aesthetics—was paired with the Kabuki spirit inherited from traditional Kabuki theater to communicate the value of individuality and self‑expression through makeup on a global scale. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260708829427/en/ KATE international campaign “KABUKE: Break Convention” key visual. Dedicated website: https://www.kate-global.net/my/special/kate_kabuki/ Since its founding, KATE has championed the slogan “NO MORE RULES.,” offering makeup that defi
Meiji Seika Pharma: Results from the Global Phase III Trial (Integral-2) of Nacubactam, a Novel β-Lactamase Inhibitor, Highlighted in The Lancet Microbe’s Coverage of ESCMID Global Congress 202617.7.2026 03:00:00 CEST | Press release
Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, President and Representative Director: Toshiaki Nagasato) today announced that results from the global Phase III trial (Integral-2) of nacubactam (Development Code: OP0595), a novel β-lactamase inhibitor, were highlighted in The Lancet Microbe’s coverage of ESCMID Global Congress 2026 (held in Munich, Germany). As highlighted in The Lancet Microbe’s coverage, the key findings presented by Meiji Seika Pharma at ESCMID Global Congress 2026 are as follows: The Integral-2 study (jRCT2031230076) is a global Phase III clinical trial that enrolled patients with complicated urinary tract infections, acute uncomplicated pyelonephritis, hospital-acquired bacterial pneumonia, ventilator-associated bacterial pneumonia, or complicated intra-abdominal infections caused by carbapenem-resistant Gram-negative bacteria (excluding Acinetobacter species). The study has achieved the prespecified study objectives. For the primary endpoint of overall treatme
Yoshihiro Shimamura Joins the Marché du Film’s “Investors Circle 2026” as an Invited Investor, Backing a New Feature Film17.7.2026 03:00:00 CEST | Press release
Shimamura Yoshihiro Film Production Co., Ltd. (Head office: Osaka, Japan; Representative Director: Yoshihiro Shimamura), a company active in film production and investment, today announced that Representative Director Yoshihiro Shimamura has decided to invest in an international feature film after being invited to the “Investors Circle 2026” — a distinction that reflects his standing as one of the field’s most highly regarded producers and investors. Hosted by the Marché du Film, the business arm of the Festival de Cannes and one of the world’s largest film markets, the Investors Circle is an invitation-only summit that connects a select group of private investors with high-end feature films during early-stage financing. Held in Cannes, France, May 16-17, 2026, it brings internationally acclaimed directors and producers together with investors around a curated slate of projects in development. During the summit, Shimamura attended private pitching sessions and, after individual meeting
Takeda’s Zasocitinib Demonstrates Consistent, High Rates of Skin Clearance Across the Body, Including Hard-to-Treat and High-Impact Sites, in Phase 3 Psoriasis Studies17.7.2026 00:00:00 CEST | Press release
On average, about 75% of patients with scalp psoriasis treated with zasocitinib achieved clear or almost clear skin at week 16 Approximately 70% of patients with palmoplantar disease treated with zasocitinib achieved clear or almost clear skin at week 16 Zasocitinib demonstrated statistically significant improvements in Nail Psoriasis Severity Index (NAPSI) versus placebo Results reinforce the potential of zasocitinib to deliver rapid and durable skin clearance, including in the hardest-to-treat areas, in a convenient once-daily pill Takeda (TSE:4502/NYSE:TAK) announced new data from the two pivotal Phase 3 studies of zasocitinib (TAK-279), a next-generation, highly selective and potent oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented at the 2026 American Academy of Dermatology (AAD) Innovation Academy, these secondary endpoint data show that zasocitinib demonstrated consistent and high rates of skin clearance across hard-to-
Merz Completes Inaugural €450 Million Schuldschein Loan Issuance16.7.2026 23:36:00 CEST | Press release
Debut transaction more than three times oversubscribed The Merz Group has successfully completed its first-ever Schuldschein loan issuance, placing a total volume of €450 million in the debt capital market – a multiple of three relating to the launch volume. The debut transaction was significantly oversubscribed and attracted strong interest from all investor groups. The proceeds were settled and paid out today. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260716926041/en/ Dr. Almuth Steinkühler, Chief Financial Officer Merz Group The transaction comprises both fixed- and floating-rate tranches with maturities of three, five, seven, and ten years. Around 50 German and international investors participated, representing a broad range of institutions, including private banks, German federal state-owned banks, public savings banks, cooperative banks, pension funds and occupational pension institutions. With the successful plac
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom